New drug aims to fix anemia after stem cell transplants
NCT ID NCT07362095
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a drug called luspatercept (Reblozyl) to treat anemia in 46 people with acute leukemia who have had a stem cell transplant. The drug is given as a shot one and four weeks after transplant. The main goal is to see if it raises hemoglobin levels and reduces the need for blood transfusions. Researchers will also watch for side effects like infections or graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
luspatercept (Reblozyl)
What this could lead to
If it works, this could offer a new way to treat anemia after stem cell transplant, reducing the need for blood transfusions and improving recovery.
What could go wrong
This is a very early, small study (46 people) with no comparison group. The drug may not improve hemoglobin levels, and risks like graft-versus-host disease or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhujiang Hospital
RECRUITINGGuangzhou, Guangdong, China
Contact